Literature DB >> 19877243

When does Parkinson's disease begin?

Carles Gaig1, Eduardo Tolosa.   

Abstract

Pathological and neuroimaging studies have shown that in Parkinson's disease (PD) there is a "subclinical" or "premotor" period during which dopaminergic neurons in the substantia nigra (SN) degenerate but typical motor symptoms have not yet developed. Post-mortem studies based on nigral cell counts and evaluating dopamine levels in the striata, and imaging studies assessing the nigrostriatal pathway in vivo, have estimated that this time period could last 3 to 6 years. In addition, emerging evidence indicates that the neuropathological process of PD does not start in the SN but more likely elsewhere in the nervous system: in the lower brainstem and the olfactory bulb, or even more distant from the SN, such as in the peripheral autonomic nervous system. Patients with PD frequently can present non-motor symptoms, such as hyposmia or constipation, years before the development of classical motor signs. The physiopathology of these "premotor" symptoms, though still unclear, is currently thought to be related to early involvement by the pathological process underlying PD of non-dopaminergic lower brainstem structures or autonomic plexuses. However, the answer to the question "when does PD start" remains uncertain. Here, we review clinical, pathological, and neuroimaging data related to the onset of the pathological process of PD, and propose that its onset is non-motor and that non-motor symptoms could begin in many instances 10 and 20 years before onset of motor symptoms. The variable course of the disorder once the motor symptoms develop, suggests that the start and progression of premotor PD is also highly variable and given the heterogeneous nature of PD, may differ depending on the cause/s of the syndrome. When and where the neuropathological process develops in PD remains uncertain. Copyright 2009 Movement Disorder Society

Entities:  

Mesh:

Year:  2009        PMID: 19877243     DOI: 10.1002/mds.22672

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  39 in total

1.  In patient's with Parkinson disease, autonomic symptoms are frequent and associated with other non-motor symptoms.

Authors:  Valentina Arnao; Antonio Cinturino; Francesca Valentino; Valentina Perini; Sergio Mastrilli; Gabriele Bellavia; Giovanni Savettieri; Sabrina Realmuto; Marco D'Amelio
Journal:  Clin Auton Res       Date:  2015-09-10       Impact factor: 4.435

Review 2.  Therapeutic Potential of Genipin in Central Neurodegenerative Diseases.

Authors:  Yanwei Li; Lin Li; Christian Hölscher
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

Review 3.  Therapeutic Potential of Baicalein in Alzheimer's Disease and Parkinson's Disease.

Authors:  Yanwei Li; Jinying Zhao; Christian Hölscher
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

4.  The association between Mediterranean diet adherence and Parkinson's disease.

Authors:  Roy N Alcalay; Yian Gu; Helen Mejia-Santana; Lucien Cote; Karen S Marder; Nikolaos Scarmeas
Journal:  Mov Disord       Date:  2012-02-07       Impact factor: 10.338

Review 5.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

6.  Reduced risk of Parkinson's disease associated with lower body mass index and heavy leisure-time physical activity.

Authors:  Katri Sääksjärvi; Paul Knekt; Satu Männistö; Jukka Lyytinen; Tuija Jääskeläinen; Noora Kanerva; Markku Heliövaara
Journal:  Eur J Epidemiol       Date:  2014-03-16       Impact factor: 8.082

Review 7.  Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?

Authors:  Marina Romero-Ramos; Marianne von Euler Chelpin; Vanesa Sanchez-Guajardo
Journal:  Hum Vaccin Immunother       Date:  2014-03-26       Impact factor: 3.452

Review 8.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

9.  Malfunctioning DNA damage response (DDR) leads to the degeneration of nigro-striatal pathway in mouse brain.

Authors:  Michal Kirshner; Ronit Galron; Dan Frenkel; Gil Mandelbaum; Yosef Shiloh; Zhao-Qi Wang; Ari Barzilai
Journal:  J Mol Neurosci       Date:  2011-09-16       Impact factor: 3.444

Review 10.  Olfactory loss as a supporting feature in the diagnosis of Parkinson's disease: a pragmatic approach.

Authors:  Katie Hoyles; Jagdish C Sharma
Journal:  J Neurol       Date:  2013-02-03       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.